Patient safety in the perioperative period is of utmost importance to anesthesiologists and health care professionals involved in the perioperative care of surgical patients. Critical events could occur at any moment during high-risk surgeries, especially cardiothoracic and transplant surgeries, because of both patient-specific characteristics and the invasiveness of procedures. Early recognition, understanding common causes, rapid diagnosis with point of care tools, and targeted treatment strategies are keys to prevent or mitigate morbidity and improve outcomes in these patients. The Seminars in Cardiothoracic and Vascular Anesthesia aims and thrives to provide such knowledge through publications of evidence and expert guidance on how to manage these potential critical events in our September 2019 issue.
Diagnosis and appropriate management of ischemic mitral regurgitation (IMR) with concomitant coronary artery bypass grafting (CABG) surgery is a highly controversial topic, and a potentially challenging entity to understand and manage for anesthesiologists. Drs Jha and Malik have provided an excellent summary of evidence related to IMR with concomitant CABG to facilitate the decision making for the perioperative management of this entity. 1 They proposed to use projected effective regurgitant orifice area and projected regurgitant volume to classify the severity of IMR adequately and create uniformity for future clinical trials on IMR management and subsequent prognosis regarding heart failure. Preoperative or intraoperative identification of predictors of successful outcome after mitral valve repair is required to reduce any potential ambiguity about clinical decision making. The presence of any of these predictors exceeding their defined cutoffs for either effective regurgitant orifice area or projected regurgitant volume may guide us to suggest the superiority of mitral valve repair over no intervention. Furthermore, desynchrony, higher wall motion score index, and septallateral delay may not predict sufficiently mitral regurgitation recurrence after coronary revascularization alone. Thus, the article of Drs Jha and Malik presents a comprehensive point of care management approach to patients with IMR undergoing CABG, and it has provided an excellent guidance to help overcome challenges as part of the clinical decision-making process. 1 Managing critical aortic valve stenosis has been forever changed by the advancement of transcatheter aortic valve replacement (TAVR). Many view TAVR as a simpler and safer alternative to surgical aortic valve replacement. However, there are still many challenges for cardiac anesthesiologists during TAVR, and failure to recognize and appropriately handle these challenges could mean a higher risk for periprocedural morbidity and mortality. Goeddel and colleagues described the differences between the currently available TAVR valves, review approaches to surgical technique, discuss anesthetic considerations, and provide their point of view on future directions, trends, and challenges. 2 The incidence of vascular injury, perivalvular leak, stroke, a need for permanent pacemaker implantation, and long-term durability of TAVR are some of the frequently occurring and highly relevant aspects of TAVR procedure. Indeed, TAVR was recently approved for intermediate-risk patients (surgical risk score of 4% to 8%), and new studies have shown excellent results in low-risk patients (surgical risk less than 4%).
3 Given the quick pace at which this technology is evolving, we must continue to keep our knowledge of the most important issues, trends, and developments up-to-date to anticipate issue surrounding TAVR implementation, and to contribute and improve care of these patients.
Patients scheduled for vascular noncardiac surgery are known to be at a higher risk for major adverse cardiac events (MACE), and many cardiac anesthesiologists are often involved in the care of high-risk vascular surgery patients. Reis and colleagues evaluated the incidence and predictors of MACE, and compared the Revised Cardiac Risk Index (RCRI), Vascular Quality Initiative (VQI-CRI), Vascular Study Group of New England (VSG-CRI), and South African Vascular Surgical (SAVS-CRI) Cardiac Risk Index to predict MACE after vascular surgery. They found that the observed MACE were within the predicted range (1% to 5% after intermediate-risk surgery and >5% after high-risk surgery). They identified previous history of coronary artery disease, atrial fibrillation, insulin-treated diabetes mellitus, a need for postoperative mechanical ventilation, and heart rate at admission as independent risk factors for MACE in their study population. 4 Careful patient selection for vascular surgery, ability to identify high-risk patients, and timely diagnosis and management of MACE are all relevant factors in the prevention of perioperative adverse cardiac events in patients undergoing vascular surgery.
As part of our transplant forum, hemostatic imbalance during liver transplantation and pain management after liver resection have been studied by 2 excellent contributions. End-stage liver disease is characterized by an unstable and precarious imbalance of both coagulation and fibrinolysis. The increased level of tissue plasminogen activator and decreased levels of thrombin activatable fibrinolysis inhibitor and plasmin inhibitor in end-stage liver disease favor hyperfibrinolysis, while decreased plasminogen level and increased plasminogen activator inhibitor level favor hypofibrinolysis, more commonly referred to as fibrinolytic shutdown. 5 Raveh and colleagues found that fibrinolytic shutdown occurred in 57% of transplant patients, with higher incidence in recipients of liver transplant. Fibrinolytic shutdown was associated with an increase in both intraoperative thrombosis and hemorrhage. Intraoperative thrombosis occurred only with liver transplantation, and accounted for 36% of in-hospital mortality. A clinically meaningful reduction in incidence of intraoperative thrombosis was noted in recipients who received intravenous heparin thromboprophylaxis in the absence of an increase in transfusion demand. This finding underscores heparin's potential for thromboprophylaxis in visceral transplantation. 6 A conduct of well-controlled, randomized clinical trials will be necessary to elucidate whether heparin administration is useful and safe to prevent thrombosis during visceral organ transplantation.
Intraoperative anesthetic decision making may influence tumor recurrence and patient survival following surgical resection of cancer. 7 Recent research has focused on the potential use of neuraxial anesthesia and opioids, and how they may affect cancer recurrence and survival after surgery cancer resection. In their study, Smith and colleagues identified a significant association between intrathecal morphine administration and 5-year survival after liver resection, which did not persist after propensity matching. This difference may be attributable to bias in the nonmatched analysis, or to a lack of power in the propensitymatched cohort. 8 The potential benefit of intrathecal opioid administration as an adjunct to general anesthesia requires further exploration to determine how intrathecal opioid administration could contribute to improved outcomes beyond analgesia. Currently, there are 2 ongoing clinical trials that aim to determine whether intrathecal opioid administration is associated with a significant improvement in survival after cancer surgery. The first trial led by Dr Grat (NCT03620916) from University of Warsaw in Poland aims to compare the effectiveness of postoperative analgesia using single-dose intrathecal morphine versus intravenous morphine in patients undergoing liver resection. This single-blinded study will enroll 36 patients randomized either to an experimental treatment opioid-based regimen or to a control group. Patients in the experimental group will receive a single-dose (0.4 mg) intrathecal morphine immediately before operation followed by patient-controlled analgesia with morphine over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale >4) administration over the next 2 days in the postoperative period. Patients in the control group (n = 18) will receive a single dose of intravenous morphine (0.15 mg/kg body mass) immediately after the operation and patient-controlled analgesia with morphine over the first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale >4) over the next 2 days. The clinical challenges forum concludes this issue of the Seminars in Cardiothoracic and Vascular Anesthesia, and our readers will have the opportunity to learn more about some of the potential complications and their respective managements that could occur in our practice such as tracheal injury prior to sternotomy, 9 massive air embolism during cardiopulmonary bypass, 10 removal of retained bronchial tissue glue after repair of a disrupted left main bronchus, 11 and a rare case of inferior vena cava stenosis after heart transplantation. 12 In summary, we present our readers with a highly pertinent set of articles with the ultimate objective on how to manage critical events that present themselves during or immediately after cardiothoracic and transplant surgery. These topics are important to master for safe patient care and are stimulating to design future clinical trials.
